Literature DB >> 31512278

Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study.

Dong Hyun Sinn1, Danbee Kang2, Yoosoo Chang3, Seungho Ryu3, Soo Jin Cho4, Seung Woon Paik1, Young Bin Song1, Roberto Pastor-Barriuso5,6, Eliseo Guallar7,8, Juhee Cho2,7,8, Geum-Youn Gwak1.   

Abstract

BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease associated with an increased risk of cardiovascular disease (CVD), diabetes, and chronic kidney disease. Indeed, CVD is the most common cause of death in NAFLD patients. This study aimed to evaluate the association between NAFLD and the risk of incident myocardial infarction.
METHODS: This is a retrospective cohort study involving 111 492 adults over 40 years old without history of CVD, liver disease, or cancer at baseline who participated in a regular health screening exam between 2003 and 2013. Fatty liver was diagnosed by ultrasonography.
RESULTS: During 725 706.9 person-years of follow-up, 183 participants developed myocardial infarction (incidence rate 0.3 cases per 1000 person-years). The age, sex, and year of visit-adjusted hazard ratio (HR) for incident myocardial infarction comparing participants with NAFLD with those without it was 2.14 (95% confidence interval 1.59, 2.89). This association remained significant in fully adjusted models (HR 1.54; 95% confidence interval 1.11, 2.14). Compared with participants without NAFLD, in participants with low NAFLD fibrosis score (NFS) (< -1.455) and with intermediate-to-high NFS (≥ -1.455), the fully adjusted HRs for incident myocardial infarction were 1.70 (1.22, 2.36) and 1.88 (1.24, 2.87), respectively.
CONCLUSION: In this large cohort study, NAFLD was associated with an increased incidence of myocardial infarction independently of established risk factors. In addition, this association was similar in participants with and without evidence of more advanced NAFLD as indicated by the NFS. NAFLD patients may need to be carefully monitored and managed early to prevent myocardial infarction.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  fibrosis; myocardial infarction; non-alcoholic fatty liver disease; risk factor

Year:  2019        PMID: 31512278     DOI: 10.1111/jgh.14856

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  13 in total

1.  Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease.

Authors:  Stefano Fiorucci; Pasquale Rapacciuolo; Bianca Fiorillo; Rosalinda Roselli; Silvia Marchianò; Cristina Di Giorgio; Martina Bordoni; Rachele Bellini; Chiara Cassiano; Paolo Conflitti; Bruno Catalanotti; Vittorio Limongelli; Valentina Sepe; Michele Biagioli; Angela Zampella
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

Review 2.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

3.  Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction.

Authors:  Weiran Dai; Yue Sun; Zhiyuan Jiang; Kuan Du; Ning Xia; Guoqiang Zhong
Journal:  Med Sci Monit       Date:  2020-06-28

4.  Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden.

Authors:  Dimitrios Ioannis Patoulias
Journal:  Arch Med Sci Atheroscler Dis       Date:  2019-12-02

Review 5.  Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease.

Authors:  Ines C M Simoes; Justyna Janikiewicz; Judith Bauer; Agnieszka Karkucinska-Wieckowska; Piotr Kalinowski; Agnieszka Dobrzyń; Andrzej Wolski; Maciej Pronicki; Krzysztof Zieniewicz; Paweł Dobrzyń; Marcin Krawczyk; Hans Zischka; Mariusz R Wieckowski; Yaiza Potes
Journal:  Nutrients       Date:  2019-11-24       Impact factor: 5.717

6.  Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China.

Authors:  Yansong Lin; Xiaorong Gong; Xin Li; Congxiang Shao; Tingfeng Wu; Minrui Li; Fuxi Li; Qianqian Ma; Junzhao Ye; Bihui Zhong
Journal:  Front Med (Lausanne)       Date:  2021-01-12

Review 7.  Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.

Authors:  Ojus Sardana; Ravi Goyal; Onkar Bedi
Journal:  Inflammopharmacology       Date:  2021-06-29       Impact factor: 4.473

8.  Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Anika Nier; Yvonne Huber; Christian Labenz; Maurice Michel; Ina Bergheim; Jörn M Schattenberg
Journal:  Nutrients       Date:  2020-03-05       Impact factor: 5.717

9.  Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease.

Authors:  Theresa Hydes; Ryan Buchanan; Oliver J Kennedy; Simon Fraser; Julie Parkes; Paul Roderick
Journal:  BMJ Open       Date:  2020-09-28       Impact factor: 2.692

Review 10.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.